Cargando…
Network pharmacology and computer-aided drug design to explored potential targets of Lianhua Qingwen and Qingfei Paidu decoction for COVID-19
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, has spread globally, affecting people’s lives worldwide and hindering global development. Traditional Chinese Medicine (TCM) plays a unique role in preventing and treating COVID-19. Representative prescriptions for the COVID-19 treatment, Lia...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540507/ https://www.ncbi.nlm.nih.gov/pubmed/36210820 http://dx.doi.org/10.3389/fphar.2022.1013428 |
_version_ | 1784803721413132288 |
---|---|
author | Li, Liyuan Wang, Xiaoying Guo, Xiao Li, Yikun Song, Qiuhang Li, Aiying |
author_facet | Li, Liyuan Wang, Xiaoying Guo, Xiao Li, Yikun Song, Qiuhang Li, Aiying |
author_sort | Li, Liyuan |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, has spread globally, affecting people’s lives worldwide and hindering global development. Traditional Chinese Medicine (TCM) plays a unique role in preventing and treating COVID-19. Representative prescriptions for the COVID-19 treatment, Lianhua Qingwen (LHQW) and Qingfei Paidu Decoction (QFPD), effectively alleviate COVID-19 symptoms, delaying its progression and preventing its occurrence. Despite the extensive similarity in their therapeutic effects, the mechanisms and advantages of LHQW and QFPD in in treating mild-to-moderate COVID-19 remain elusive. To characterize the mechanisms of LHQW and QFPD in treating COVID-19, we used integrated network pharmacology and system biology to compare the LHQW and QFPD components, active compounds and their targets in Homo sapiens. LHQW and QFPD comprise 196 and 310 active compounds, some of which have identical targets. These targets are enriched in pathways associated with inflammation, immunity, apoptosis, oxidative stress, etc. However, the two TCM formulas also have specific active compounds and targets. In LHQW, arctiin, corymbosin, and aloe-emodin target neurological disease-related genes (GRM1 and GRM5), whereas in QFPD, isofucosterol, baicalein, nobiletin, oroxylin A, epiberberine, and piperlonguminine target immunity- and inflammation-related genes (mTOR and PLA2G4A). Our findings indicate that LHQW may be suitable for treating mild-to-moderate COVID-19 with nervous system symptoms. Moreover, QFPD may effectively regulate oxidative stress damage and inflammatory symptoms induced by SARS-CoV-2. These findings may provide references for the clinical application of LHQW and QFPD. |
format | Online Article Text |
id | pubmed-9540507 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95405072022-10-08 Network pharmacology and computer-aided drug design to explored potential targets of Lianhua Qingwen and Qingfei Paidu decoction for COVID-19 Li, Liyuan Wang, Xiaoying Guo, Xiao Li, Yikun Song, Qiuhang Li, Aiying Front Pharmacol Pharmacology Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, has spread globally, affecting people’s lives worldwide and hindering global development. Traditional Chinese Medicine (TCM) plays a unique role in preventing and treating COVID-19. Representative prescriptions for the COVID-19 treatment, Lianhua Qingwen (LHQW) and Qingfei Paidu Decoction (QFPD), effectively alleviate COVID-19 symptoms, delaying its progression and preventing its occurrence. Despite the extensive similarity in their therapeutic effects, the mechanisms and advantages of LHQW and QFPD in in treating mild-to-moderate COVID-19 remain elusive. To characterize the mechanisms of LHQW and QFPD in treating COVID-19, we used integrated network pharmacology and system biology to compare the LHQW and QFPD components, active compounds and their targets in Homo sapiens. LHQW and QFPD comprise 196 and 310 active compounds, some of which have identical targets. These targets are enriched in pathways associated with inflammation, immunity, apoptosis, oxidative stress, etc. However, the two TCM formulas also have specific active compounds and targets. In LHQW, arctiin, corymbosin, and aloe-emodin target neurological disease-related genes (GRM1 and GRM5), whereas in QFPD, isofucosterol, baicalein, nobiletin, oroxylin A, epiberberine, and piperlonguminine target immunity- and inflammation-related genes (mTOR and PLA2G4A). Our findings indicate that LHQW may be suitable for treating mild-to-moderate COVID-19 with nervous system symptoms. Moreover, QFPD may effectively regulate oxidative stress damage and inflammatory symptoms induced by SARS-CoV-2. These findings may provide references for the clinical application of LHQW and QFPD. Frontiers Media S.A. 2022-09-23 /pmc/articles/PMC9540507/ /pubmed/36210820 http://dx.doi.org/10.3389/fphar.2022.1013428 Text en Copyright © 2022 Li, Wang, Guo, Li, Song and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Li, Liyuan Wang, Xiaoying Guo, Xiao Li, Yikun Song, Qiuhang Li, Aiying Network pharmacology and computer-aided drug design to explored potential targets of Lianhua Qingwen and Qingfei Paidu decoction for COVID-19 |
title | Network pharmacology and computer-aided drug design to explored potential targets of Lianhua Qingwen and Qingfei Paidu decoction for COVID-19 |
title_full | Network pharmacology and computer-aided drug design to explored potential targets of Lianhua Qingwen and Qingfei Paidu decoction for COVID-19 |
title_fullStr | Network pharmacology and computer-aided drug design to explored potential targets of Lianhua Qingwen and Qingfei Paidu decoction for COVID-19 |
title_full_unstemmed | Network pharmacology and computer-aided drug design to explored potential targets of Lianhua Qingwen and Qingfei Paidu decoction for COVID-19 |
title_short | Network pharmacology and computer-aided drug design to explored potential targets of Lianhua Qingwen and Qingfei Paidu decoction for COVID-19 |
title_sort | network pharmacology and computer-aided drug design to explored potential targets of lianhua qingwen and qingfei paidu decoction for covid-19 |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540507/ https://www.ncbi.nlm.nih.gov/pubmed/36210820 http://dx.doi.org/10.3389/fphar.2022.1013428 |
work_keys_str_mv | AT liliyuan networkpharmacologyandcomputeraideddrugdesigntoexploredpotentialtargetsoflianhuaqingwenandqingfeipaidudecoctionforcovid19 AT wangxiaoying networkpharmacologyandcomputeraideddrugdesigntoexploredpotentialtargetsoflianhuaqingwenandqingfeipaidudecoctionforcovid19 AT guoxiao networkpharmacologyandcomputeraideddrugdesigntoexploredpotentialtargetsoflianhuaqingwenandqingfeipaidudecoctionforcovid19 AT liyikun networkpharmacologyandcomputeraideddrugdesigntoexploredpotentialtargetsoflianhuaqingwenandqingfeipaidudecoctionforcovid19 AT songqiuhang networkpharmacologyandcomputeraideddrugdesigntoexploredpotentialtargetsoflianhuaqingwenandqingfeipaidudecoctionforcovid19 AT liaiying networkpharmacologyandcomputeraideddrugdesigntoexploredpotentialtargetsoflianhuaqingwenandqingfeipaidudecoctionforcovid19 |